Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.
| Image |  |
|---|---|
| Description | scholarly article |
| Author/s |
author: Shigeru Chiba |
| Publication date | November 20, 2009 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Access work | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |